ERBB2 and adenocarcinoma: The Phase III KEYNOTE-859 trial randomized 1579 patients with treatment-naïve, HER2-, advanced G/GEJ adenocarcinoma to receive either pembrolizumab + chemotherapy (FP or CAPOX) or chemotherapy alone [4].